Fidelity Biosciences News - Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies.

News Highlights:

U.S. Genomics and Northrop Grumman Sign Teaming Agreement

December 19, 2006 - U.S Genomics Inc. and the Northrop Grumman Corporation (NYSE: NOC) have signed a teaming agreement to work together to commercialize U.S. Genomics' single molecule detection technology. View Full Article

Intranasal Therapeutics, Inc. Adds Key Executives to Management Team

December 6, 2006 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, announced today the appointment of two key executives to its management team. Franz F. Hefti, Ph.D., who has... View Full Article

Drug fights off disease but attracts investors

November 24, 2006 - Fledgling startup TetraPhase Pharmaceuticals Inc. has nailed down $25 million in a first round of venture financing toward developing treatments for drug-resistant infections. View Full Article

MethylGene and EnVivo Pharmaceuticals Form Collaboration with CHDI, Inc., in Support of HDAC Program for Huntington’s Disease

November 16, 2006 - MethylGene Inc. (TSX: MYG) with its collaborator EnVivo Pharmaceuticals, today announced that they have entered into a collaborative agreement with CHDI, Inc., a non-profit organization that is pursuing biotechnology approaches to rapidly discover and... View Full Article

EnVivo Pharmaceuticals Forms Research Collaboration With CHDI

October 25, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has established a research collaboration agreement with CHDI, Inc., a non-profit organization dedicated to... View Full Article

Linaclotide shown to improve symptoms of chronic constipation in phase 2A study

October 24, 2006 - Microbia today announced the presentation of data from a Phase 2a study demonstrating that treatment with linaclotide (MD-1100) improved bowel function in patients with chronic constipation. Treatment with linaclotide increased frequency of... View Full Article

U.S. Genomics and Lahey Clinic Announce Collaboration to Study the Role of microRNAs

October 17, 2006 - U.S Genomics Inc. and Lahey Clinic announce the signing of a discovery agreement to study the role microRNAs play in the development of urological cancers. The objective of the collaboration is to develop more accurate prognoses for bladder and... View Full Article

Envivo secures $24 million series C financing

October 4, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has secured $24 million in Series C financing led by existing investor Fidelity Biosciences. The company also said that... View Full Article

Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer

October 1, 2006 - Transave Inc., a biopharmaceutical company developing drugs for life-threatening lung diseases, today announced the appointment of Renu Gupta, M.D., as Executive Vice President of Development and Chief Medical Officer. View Full Article

TRANSAVE’S SLIT™ AMIKACIN IS GRANTED ORPHAN DRUG DESIGNATION BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA LUNG INFECTIONS IN CYSTIC FIBROSIS

August 2, 2006 - Transave, Inc., a biopharmaceutical company focused on the development of inhaled, liposomal formulation of drugs for treating life threatening lung diseases, today announced that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted... View Full Article

FoldRx Pharmaceuticals Closes $43 Million Series B Financing

May 30, 2006 - FoldRx Pharmaceuticals, Inc., a development-stage biotechnology company focused on protein misfolding diseases, announced today that it has successfully raised $43 million in a Series B financing. The funds will be used for the continued clinical development of... View Full Article

Envivo Expands Management Team As Company Prepares First Drugs For Clinical Trials

May 23, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has strengthened its management team with the appointment of Michael K. Ahlijanian, Ph.D. as Vice President, Research and... View Full Article

Microbia presents MD-1100 (Linaclotide Acetate) phase 1 results

May 23, 2006 - Microbia, Inc. today announced presentation of data from clinical and nonclinical studies with MD-1100 (linaclotide acetate), the Company’s first-in-class investigational drug for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic... View Full Article

Cardiokine, Inc. Closes $50 Million Series B Financing

May 1, 2006 - Cardiokine, Inc., a specialty pharmaceutical company focused on the development of drugs for the treatment and prevention of heart failure and related cardiovascular and metabolic indications, announced today the closing of a $50 million Series B preferred share equity offering. View Full Article

Transave, Inc. Appoints Donald Hayden, Jr. Executive Chairman Of Its Board Of Directors

April 28, 2006 - Transave Inc., a biopharmaceutical company developing inhaled liposomal formulated drugs for treating life threatening lung disease, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Hayden is... View Full Article

Mersana Therapeutics, Inc. Appoints Key Members of Management Team

March 21, 2006 - Mersana, a privately-held cancer therapeutics company, announced today that Russell C. Petter, PhD, has joined the company as Vice President of Research and Ullrich S. Schwertschlag, MD, PhD as Vice President of Clinical Development. View Full Article

Microbia Raises $75 Million In Private Equity Financing To Advance Therapeutic Candidates Through Clinical Trials

February 27, 2006 - Microbia, Inc., an entrepreneurial pharmaceutical company with two internally discovered drug candidates in clinical trials, today announced it has raised $75 million in a series E private equity financing. In addition, the company announced the initiation of... View Full Article